[Treatment of degenerative dementia disorders--who should be treated?].
Recommendations for treatment with specific antidementia drugs in Denmark are given on the basis of recent evidence. Such evidence supports treatment of mild to moderate Alzheimer's Disease (AD) with acetylcholinesterase inhibitors (AchEI), and moderate to severe AD with memantine. Combination therapy with these drugs can be considered in moderate AD. Dementia with Lewy bodies and Parkinson's disease with dementia should be treated with rivastigmine. There is not sufficient evidence to recommend treatment with AchEI or memantine in pure vascular dementia or frontotemporal dementia.
Hasselbalch
Steen G
SG
Hukommelsesklinikken N6702, Rigshospitalet, DK-2100 København Ø. steen.hasselbalch@rh.regionh.dk
Kampmann
Jens Peter
JP
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003704:Dementia / Q000150:complications / Q000188:drug therapy*; D015259:Dopamine Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D020961:Lewy Body Disease / Q000188:drug therapy; D008559:Memantine / Q000627:therapeutic use; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy; D018579:Patient Selection; D048448:Phenylcarbamates / Q000627:therapeutic use; D000068836:Rivastigmine
D000978:Antiparkinson Agents; D002800:Cholinesterase Inhibitors; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine; D008559:Memantine